RADIONUCLIDE THERAPY FOR BONE LESIONS IN CASTRATION-RESISTANT PROSTATE CANCER (STATE-OF-THE-ART LITERATURE REVIEW).

Abstract

The scope of scientific literature was reviewed to summarize the data on the 223Radichloride therapy for castration resistant forms of prostate cancer. Key advantages of the alphaemitters over betaemitting radionuclides are highlighted in the treatment of hormoneresistant bone metastases. Data demonstrating an association between the 223Radichloride treatment effectiveness and absorbed therapeutic doses were analyzed. Dependence between the 223Ra and 18Ffluoride absorbed doses in bone metastases was evaluated, which should be taken into account in a positron emission tomography monitoring. Results of studies examining the uptake of 18Ffluoride to predict the 223Radichloride accumulation during the first course of treatment were analyzed. Research areas requiring further concern have been identified through the literature review, namely: study of the relationship between an absorbed dose and other clinically relevant endpoints, including pain index, changes in alkaline phosphatase or prostate antigen levels, survival rates, and development of alternative treatment regimens depending on the therapeutic radiopharmaceutical dose.